StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Imfinzi (durvalumab) — Emerging Markets YoY CER by Quarter

Imfinzi (durvalumab) — Emerging Markets YoY CER (%) (%)

QuarterlyAnnual

AstraZeneca Imfinzi (durvalumab) — Emerging Markets YoY CER: 36.0% in Q2 2026, up 1.0 pts from a year earlier.

Latest, Q2 2026
36.0%
Period ended Jun 30, 2026
Change on a year earlier
+1.0 pts
35.0% in Q2 2025
History
21 quarters
Since Q1 2021
Sources
21
Documents cited below

Where the Q2 2026 figure comes from

“|| Imfinzi | 1,854 | | 27 | | 27 | | 1,054 | | 25 | | 211 | | 39 | | 36 | | 398 | | 39 | | 34 | | 191 | | 10 | | 17”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedImfinzi (durvalumab) — Emerging Markets YoY CER (%) (%)Year on yearSource
Q2 2026Jun 30, 202636.0%+1.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202628.0%+8.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202553.0%0.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202544.0%-22.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202535.0%-4.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202520.0%-63.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202453.0%-11.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202466.0%+59.0 ptsForm 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202439.0%-8.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202483.0%+36.0 ptsForm 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202364.0%+61.0 ptsForm 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20237.0%-12.0 ptsForm 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202347.0%+46.0 ptsForm 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202347.0%+44.0 ptsForm 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20223.0%-41.0 ptsForm 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202219.0%-31.0 ptsForm 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Imfinzi (durvalumab) — Emerging Markets YoY CER (%), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-imfinzi-em-cer-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.